Strategic Partnerships Target partnerships with clinical research organizations and transplant/urology centers involved in renal cell carcinoma and multi-cancer early detection trials, leveraging Elypta's metabolic biomarker approach to expand study sites and accelerate validation.

Clinical Evidence Leverage Capitalize on recent AURORAX-0087A study presentations and Plenary sessions to solicit advisory board roles, speaker engagements, and collaborative opportunities with major urology conferences and academic centers.

Regulatory & reimbursement Identify pathways for early reimbursement discussions by engaging with payer pilots and health technology assessment bodies as Lypta progresses toward MCED indications, using LEVANTIS-0087A data to support value propositions.

Key Personnel Engage newly appointed board members and senior researchers to unlock introductions to tier-one diagnostic investors, strategic partners, and potential contract research organizations for large-scale studies.

Market Expansion Position the GAGome liquid biopsy as a broad multi-cancer screening tool by tailoring outreach to oncology clinics, primary care networks, and hospital systems seeking noninvasive, metabolism-based cancer detection solutions.